ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) saw unusually large options trading activity on Friday. Investors acquired 9,749 call options on the company. This is an increase of 125% compared to the average volume of 4,330 call options.
Analyst Ratings Changes
IBRX has been the subject of a number of research analyst reports. EF Hutton Acquisition Co. I raised ImmunityBio to a “strong-buy” rating in a research note on Wednesday. Piper Sandler decreased their price objective on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating for the company in a research report on Monday, August 19th.
View Our Latest Research Report on IBRX
Hedge Funds Weigh In On ImmunityBio
ImmunityBio Stock Up 26.4 %
Shares of NASDAQ:IBRX opened at $5.32 on Friday. The firm has a market cap of $3.71 billion, a price-to-earnings ratio of -5.48 and a beta of 1.02. ImmunityBio has a 12 month low of $1.62 and a 12 month high of $10.53. The company’s fifty day simple moving average is $3.72 and its 200 day simple moving average is $5.35.
ImmunityBio (NASDAQ:IBRX – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The business had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.53 million. Research analysts expect that ImmunityBio will post -0.86 earnings per share for the current fiscal year.
About ImmunityBio
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
See Also
- Five stocks we like better than ImmunityBio
- What does consumer price index measure?
- Texas Roadhouse Stock Steering for New Highs This Year
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Calculate Stock Profit
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.